1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 4: 
Absolute metabolite concentrations (and SE, in mM in aqueous fraction) in NAWM between patients with MS (and normal MRI scan of the brain) and control subjects
Absolute Metabolite ConcentrationControl Subjects, mMRRMS, mMSPMS, mM
NAA
    Mean10.9610.3410.04
    SE0.190.190.29
NAAG
    Mean3.733.592.69*
    SE0.250.250.16
tNA
    Mean14.6213.8812.68*
    SE0.260.260.28
mIns
    Mean6.186.356.45
    SE0.130.180.27
  • Note:—mIns indicates myo-inositol; NAA, N-acetylaspartate; NAAG, N-acetylaspartate glutamate; tNA, total N-acetyl compounds including NAA and NAAG; RRMS, relapsing remitting multiple sclerosis; SPMS, secondary-progressive multiple sclerosis; NAWM, normal-appearing white matter. The MS patients were separated into RRMS and SPMS.
  • * Significant difference between RRMS and SPMS, P < .05 (Mann-Whitney).